Published in Fertil Steril on October 01, 2010
Hyperandrogenemia predicts metabolic phenotype in polycystic ovary syndrome: the utility of serum androstenedione. J Clin Endocrinol Metab (2014) 1.61
Ovarian hypertension: polycystic ovary syndrome. Endocrinol Metab Clin North Am (2011) 0.85
Comparison of Drospirenone- with Cyproterone Acetate-Containing Oral Contraceptives, Combined with Metformin and Lifestyle Modifications in Women with Polycystic Ovary Syndrome and Metabolic Disorders: A Prospective Randomized Control Trial. Chin Med J (Engl) (2016) 0.80
Ethinylestradiol30μg-drospirenone and metformin: could this combination improve endothelial dysfunction in polycystic ovary syndrome? BMC Endocr Disord (2012) 0.79
The American Diabetes Association's 57th annual advanced postgraduate course: diabetes risk, vitamin D, polycystic ovary syndrome, and obstructive sleep apnea. Diabetes Care (2011) 0.77
The association of elective hormone therapy with changes in lipids among glucose intolerant postmenopausal women in the diabetes prevention program. Metabolism (2013) 0.76
Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med (2002) 5.83
Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab (2010) 2.27
The management of patients with uterine sarcoma: a debated clinical challenge. Crit Rev Oncol Hematol (2007) 1.61
Effect of long-term naltrexone treatment on endocrine profile, clinical features, and insulin sensitivity in obese women with polycystic ovary syndrome. Fertil Steril (2002) 1.45
Hormone replacement therapy and cardioprotection: a new dawn? A statement of the Study Group on Cardiovascular Disease in Women of the Italian Society of Cardiology on hormone replacement therapy in postmenopausal women. J Cardiovasc Med (Hagerstown) (2009) 1.44
The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: a review of the literature. Crit Rev Oncol Hematol (2007) 1.40
Serum tumor markers in the management of ovarian, endometrial and cervical cancer. Biomed Pharmacother (2004) 1.30
IMS updated recommendations on postmenopausal hormone therapy. Climacteric (2007) 1.20
Genomic and non-genomic effects of estrogens on endothelial cells. Steroids (2004) 1.20
Extra-nuclear signalling of estrogen receptor to breast cancer cytoskeletal remodelling, migration and invasion. PLoS One (2008) 1.14
Estrogen receptor-alpha promotes breast cancer cell motility and invasion via focal adhesion kinase and N-WASP. Mol Endocrinol (2010) 1.12
Polycystic ovary syndrome and gynecological cancers: is there a link? Gynecol Endocrinol (2005) 1.12
Management of cardiovascular risk in the peri-menopausal woman: a consensus statement of European cardiologists and gynaecologists. Eur Heart J (2007) 1.07
New evidence regarding hormone replacement therapies is urgently required transdermal postmenopausal hormone therapy differs from oral hormone therapy in risks and benefits. Maturitas (2005) 1.03
Lymph-vascular space involvement and outer one-third myometrial invasion are strong predictors of distant haematogeneous failures in patients with stage I-II endometrioid-type endometrial cancer. Anticancer Res (2009) 1.01
Ovarian function and childbearing issues in breast cancer survivors. Gynecol Endocrinol (2007) 1.01
Serum and tissue biomarkers as predictive and prognostic variables in epithelial ovarian cancer. Crit Rev Oncol Hematol (2008) 1.01
Could transdermal estradiol + progesterone be a safer postmenopausal HRT? A review. Maturitas (2008) 1.00
Old and new perspectives in the management of high-risk, locally advanced or recurrent, and metastatic vulvar cancer. Crit Rev Oncol Hematol (2006) 1.00
Fertility drug use and risk of ovarian tumors: a debated clinical challenge. Gynecol Endocrinol (2012) 1.00
Brain-derived neurotrophic factor plasma variation during the different phases of the menstrual cycle in women with premenstrual syndrome. Psychoneuroendocrinology (2010) 0.98
Consolidation and maintenance treatments for patients with advanced epithelial ovarian cancer in complete response after first-line chemotherapy: a review of the literature. Crit Rev Oncol Hematol (2005) 0.98
EMAS position statement: Managing the menopause in the context of coronary heart disease. Maturitas (2010) 0.97
Atherogenic lipoprotein phenotype and low-density lipoproteins size and subclasses in women with polycystic ovary syndrome. J Clin Endocrinol Metab (2006) 0.95
Adolescent girls with polycystic ovary syndrome showing different phenotypes have a different metabolic profile associated with increasing androgen levels. Fertil Steril (2008) 0.95
Rapid signaling of estrogen to WAVE1 and moesin controls neuronal spine formation via the actin cytoskeleton. Mol Endocrinol (2009) 0.95
Molecular target therapies in endometrial cancer: from the basic research to the clinic. Gynecol Endocrinol (2008) 0.94
Effect of climacteric transition and hormone replacement therapy on body weight and body fat distribution. Gynecol Endocrinol (2006) 0.93
Vascular endothelial growth factor and basic fibroblast growth factor in polycystic ovary syndrome during controlled ovarian hyperstimulation. Gynecol Endocrinol (2006) 0.93
EMAS position statement: Vitamin D and postmenopausal health. Maturitas (2011) 0.92
The predictive and prognostic value of serum CA 125 half-life during paclitaxel/platinum-based chemotherapy in patients with advanced ovarian carcinoma. Gynecol Oncol (2004) 0.92
Functional hypothalamic amenorrhea: current view on neuroendocrine aberrations. Gynecol Endocrinol (2008) 0.90
Breast cancer and sex steroids: critical review of epidemiological, experimental and clinical investigations on etiopathogenesis, chemoprevention and endocrine treatment of breast cancer. Gynecol Endocrinol (2005) 0.90
Diagnosis of a variant of Mayer-Rokitansky-Kuster-Hauser syndrome: useful MRI findings. Abdom Imaging (2011) 0.89
Body mass index and body composition in adolescents treated with gonadotropin-releasing hormone analogue triptorelin depot for central precocious puberty: data at near final height. Neuroendocrinology (2009) 0.89
Spontaneous cornual pregnancy after homolateral salpingectomy for an earlier tubal pregnancy: a case report and literature review. J Minim Invasive Gynecol (2009) 0.89
Old and new perspectives in the pharmacological treatment of advanced or recurrent endometrial cancer: Hormonal therapy, chemotherapy and molecularly targeted therapies. Crit Rev Oncol Hematol (2006) 0.88
Female infertility related to thyroid autoimmunity: the ovarian follicle hypothesis. Am J Reprod Immunol (2011) 0.88
Comparative actions of progesterone, medroxyprogesterone acetate, drospirenone and nestorone on breast cancer cell migration and invasion. BMC Cancer (2008) 0.87
Oregano: a source for peroxisome proliferator-activated receptor gamma antagonists. J Agric Food Chem (2008) 0.87
Oestrogen and progestins differently prevent glutamate toxicity in cortical neurons depending on prior hormonal exposure via the induction of neural nitric oxide synthase. Steroids (2009) 0.86
Hyperandrogenemia influences the prevalence of the metabolic syndrome abnormalities in adolescents with the polycystic ovary syndrome. Gynecol Endocrinol (2009) 0.86
EMAS position statement: Managing women with premature ovarian failure. Maturitas (2010) 0.86
Rapid estrogen actions in the cardiovascular system. Ann N Y Acad Sci (2006) 0.86
Vascular endothelial growth factor and its soluble receptor in patients with polycystic ovary syndrome undergoing IVF. Hum Fertil (Camb) (2009) 0.86
Estrogen regulates endometrial cell cytoskeletal remodeling and motility via focal adhesion kinase. Fertil Steril (2010) 0.85
Biochemical prognostic factors and risk of relapses in patients with cervical cancer. Gynecol Oncol (2007) 0.85
EMAS position statement: managing obese postmenopausal women. Maturitas (2010) 0.85
Clinicopathological variables predictive of clinical outcome in patients with FIGO stage Ib2-IIb cervical cancer treated with cisplatin-based neoadjuvant chemotherapy followed by radical hysterectomy. Anticancer Res (2010) 0.85
Timing is everything. Gynecol Endocrinol (2007) 0.84
EMAS position statement: Managing menopausal women with a personal or family history of VTE. Maturitas (2011) 0.84
Chromosomal abnormalities in women with premature ovarian failure. Gynecol Endocrinol (2010) 0.84
Effect of raloxifene on cardiovascular adverse events in postmenopausal women with osteoporosis. Am J Cardiol (2006) 0.84
Therapeutic strategies for ovulation induction in infertile women with polycystic ovary syndrome. Gynecol Endocrinol (2005) 0.83
Usefulness of a simple sleep-deprived EEG protocol for epilepsy diagnosis in de novo subjects. Clin Neurophysiol (2013) 0.83
Intratumoral microvessel density in advanced epithelial ovarian cancer and its use as a prognostic variable. Anticancer Res (2006) 0.83
The perioperative management of patients with gynaecological cancer undergoing major surgery: A debated clinical challenge. Crit Rev Oncol Hematol (2009) 0.83
Ultra low-dose hormone replacement therapy and bone protection in postmenopausal women. Maturitas (2007) 0.83
Patterns of failures in endometrial cancer: clinicopathological variables predictive of the risk of local, distant and retroperitoneal failure. Anticancer Res (2011) 0.83
Effects of raloxifene on breast cancer cell migration and invasion through the actin cytoskeleton. J Cell Mol Med (2009) 0.82
Progestagen component in combined hormone replacement therapy in postmenopausal women and breast cancer risk: a debated clinical issue. Gynecol Endocrinol (2009) 0.82
Progesterone and medroxyprogesterone acetate effects on central and peripheral allopregnanolone and beta-endorphin levels. Neuroendocrinology (2006) 0.82
Chemotherapy with epirubicin and paclitaxel for breast cancer during pregnancy: case report and review of the literature. Anticancer Res (2004) 0.81
Vascular endothelial growth factor (VEGF) expression in primary tumors and peritoneal metastases from patients with advanced ovarian carcinoma. Anticancer Res (2003) 0.81
Gynaecologic challenging issues in the management of BRCA mutation carriers: oral contraceptives, prophylactic salpingo-oophorectomy and hormone replacement therapy. Gynecol Endocrinol (2010) 0.81
Tissue and serum biomarkers as prognostic variables in endometrioid-type endometrial cancer. Crit Rev Oncol Hematol (2010) 0.81
Clinico-pathological and biological prognostic variables in squamous cell carcinoma of the vulva. Crit Rev Oncol Hematol (2011) 0.81
Effect of dehydroepiandrosterone on central and peripheral levels of allopregnanolone and beta-endorphin. Fertil Steril (2005) 0.81
The fertility-sparing treatment in patients with endometrial atypical hyperplasia and early endometrial cancer: a debated therapeutic option. Gynecol Endocrinol (2009) 0.81
Estrogen receptor-{alpha} promotes endothelial cell motility through focal adhesion kinase. Mol Hum Reprod (2010) 0.80
Brain recurrences in patients with ovarian cancer: report of 12 cases and review of the literature. Anticancer Res (2008) 0.80
In vitro effects of progesterone and progestins on vascular cells. Steroids (2003) 0.80
Use of estrogen antagonists and aromatase inhibitors in breast cancer and hormonally sensitive tumors of the uterine body. Curr Opin Investig Drugs (2004) 0.79
Positive effects on cardiovascular and breast metabolic markers of oral estradiol and dydrogesterone in comparison with transdermal estradiol and norethisterone acetate. Maturitas (2002) 0.79
Effects of nomegestrol acetate administration on central and peripheral beta-endorphin and allopregnanolone in ovx rats. J Steroid Biochem Mol Biol (2008) 0.79
New insights on the pathogenesis of ovarian carcinoma: molecular basis and clinical implications. Gynecol Endocrinol (2012) 0.79
Hormonal influence on the central nervous system. Maturitas (2002) 0.79
Neutropenic enterocolitis in an advanced epithelial ovarian cancer patient treated with paclitaxel/platinum-based chemotherapy: a case report and review of the literature. Anticancer Res (2005) 0.79
Sexually dimorphic effects of testosterone administration on brain allopregnanolone in gonadectomized rats. J Sex Med (2008) 0.79
Different effect of hormone replacement therapy, DHEAS and tibolone on endothelial function in postmenopausal women with increased cardiovascular risk. Maturitas (2005) 0.79
Intratumoral microvessel density, response to chemotherapy and clinical outcome of patients with advanced ovarian carcinoma. Anticancer Res (2003) 0.79
Effect of an oral contraceptive containing 30 microg ethinylestradiol plus 3 mg drospirenone on body composition of young women affected by premenstrual syndrome with symptoms of water retention. Contraception (2007) 0.78
The management of malignant nondysgerminomatous ovarian germ cell tumors. Anticancer Res (2003) 0.78
EMAS position statement: managing the menopause in women with epilepsy. Maturitas (2010) 0.78
Hypoestrogenism in young women and its influence on bone mass density. Gynecol Endocrinol (2010) 0.78
Hormone therapy. Menopause (2003) 0.78
Feto-placental vascular dysfunction as a prenatal determinant of adult cardiovascular disease. Intern Emerg Med (2013) 0.78
EMAS position statement: Managing the menopause in women with a past history of endometriosis. Maturitas (2010) 0.77
Pattern of failures and clinical outcome of patients with locally advanced cervical cancer treated with a tailored integrated therapeutic approach. Anticancer Res (2010) 0.77